Drug intelligence / Profile preview

EF-011

Development stage: Preclinical
Lead developer: Everfront Biotech
Modality: Small Molecules

Overview

EF-011 is an investigational small molecule drug developed by Everfront Biotech for the treatment of idiopathic pulmonary fibrosis (IPF). It works by inhibiting the binding of SOX2 to the promoter of type I collagen, thereby reducing the expression and accumulation of type I collagen, which is involved in fibrosis formation. In preclinical studies, EF-011 showed significant improvement in tissue pathology and respiratory function compared to pirfenidone.

Targets

SRY-box transcription factor 2–DNA complex at the type I collagen promoterSOX2 (SRY-box transcription factor 2)

Beyond the preview

Go deeper on EF-011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EF-011.